Next&Bio Signs MOU with Cancer Science Institute of Singapore for Organoid Collaboration
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Singapore, where many global pharmaceutical companies have established R&D research centers, has demographic and geographical advantages that allow it to serve as the Asian hub for organoid-based cancer precision medicine," said Prof. Hyunsook Lee, Co-CEO of Next&Bio. "In addition, we expect to benefit from synergies in technology development resulting from collaborations with world-class scientists and clinicians at CSI Singapore on organoid-based research in Asian cancer patients, including individuals of Chinese, Malay, or Indian descent, outside of Korea. We will make further efforts to accelerate the realization of precision medicine to treat cancer by leveraging Next&Bio's organoid culture technology and CSI Singapore's unparalleled cancer research expertise."
"Cancer is highly heterogeneous from patient to patient, requiring a precision medicine approach for individualized treatment. Cancer organoids that can reproduce the heterogeneity of patient tissues in vitro play an important role in research on personalized cancer medicine," said Prof. Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at the National University of Singapore. "Scientists and clinicians who study major cancers, such as breast, colon, and liver cancer, may use cancer organoids generated in the proposed collaboration with Next&Bio to conduct research. We look forward to building an organoid bank at CSI Singapore with multiple cancer tissues to further facilitate research into individualized treatment."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Next&Bio Inc. (Co-CEO: HyunSook Lee, Ji-Hun Yang), a company that has developed an organoid-based precision medicine drug discovery and development platform, has signed a memorandum of understanding (MOU) with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) on the establishment of collaboration to realize the development of novel precision medicine therapeutics using cancer-organoids.
Under the MOU, CSI Singapore and Next&Bio will discuss opportunities to establish a joint cancer organoid laboratory, and to pursue joint projects. Under discussion will be the potential for Next&Bio to utilize their organoid culture technology to generate an organoid bank through collaborations with experts at CSI Singapore, which can be used for cancer patient-derived organoid-based research projects and developing patient-specific drug evaluation platforms using organoids.
The proposed joint cancer organoid laboratory would add to Next&Bio’s global network of organoid-based research collaborations aimed at developing organoid-based solutions for pressing research needs. The proposed collaboration with CSI Singapore will take advantage of the diverse ethnic backgrounds represented in Singapore to create an Asian hub for cancer organoid-based precision medicine.
“Singapore, where many global pharmaceutical companies have established R&D research centers, has demographic and geographical advantages that allow it to serve as the Asian hub for organoid-based cancer precision medicine,” said Prof. Hyunsook Lee, Co-CEO of Next&Bio. “In addition, we expect to benefit from synergies in technology development resulting from collaborations with world-class scientists and clinicians at CSI Singapore on organoid-based research in Asian cancer patients, including individuals of Chinese, Malay, or Indian descent, outside of Korea. We will make further efforts to accelerate the realization of precision medicine to treat cancer by leveraging Next&Bio’s organoid culture technology and CSI Singapore’s unparalleled cancer research expertise.”
“Cancer is highly heterogeneous from patient to patient, requiring a precision medicine approach for individualized treatment. Cancer organoids that can reproduce the heterogeneity of patient tissues in vitro play an important role in research on personalized cancer medicine,” said Prof. Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at the National University of Singapore. “Scientists and clinicians who study major cancers, such as breast, colon, and liver cancer, may use cancer organoids generated in the proposed collaboration with Next&Bio to conduct research. We look forward to building an organoid bank at CSI Singapore with multiple cancer tissues to further facilitate research into individualized treatment.”
About Next&Bio Inc.
Head office: Seoul National University, Building 105-2, 4F 433B, 1 Gwanak-ro, Gwanak-gu, Seoul
Laboratory: Korea University, Techno Complex Building, 6F, 602-1, 2, 145 Anam-ro, Seounbuk-gu
For additional information, please visit Next&Bio's official website.
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Next&Bio
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 현대차그룹, 2024년 대표이사·사장단 임원인사 - 뉴스와이어
- 가을밤, 한국의집 궁중다과와 고려시대 최고급 탁주에 취하다 - 뉴스와이어
- 최윤정 소리북 독주회 ‘나는 고수다 Ⅱ’ 완북 동초제 적벽가 강릉서 개최 - 뉴스와이어
- 좋은땅출판사 ‘비전공자도 이해하며 경험할 수 있는 AI 왕국’ 출간 - 뉴스와이어
- 삼성전자, 10조원 규모 자사주 매입 결정 - 뉴스와이어
- 헬리녹스, 창립 15주년 기념 100% 스케일 베어브릭 컬렉션 출시 - 뉴스와이어
- 장미와 여우, 시집 ‘마하의 시간을 살다’ 출간 - 뉴스와이어
- 쉐이퍼 글램스 울트라, 국내 약국 강남·종로·인천 78곳 입점해 소비자 만족도 상승 - 뉴스와이어
- 몰렉스, SAP 솔루션으로 지능형 공급망 협업 추진 - 뉴스와이어
- 삼성전자 노사, 2023년·2024년 임금협약 잠정합의 - 뉴스와이어